Doug Altman

Datos Biográficos

ID7620182
NOMBREDoug Altman
NOMBRESDoug
APELLIDOAltman
FIRMAALTMAN D
AFILIACIONESUniversity of Oxford
VERIFICADONo
TOTAL DE OBRAS8
TOTAL DE CITAS0
TOTAL COMO AUTOR8
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN1995
AÑO MÁS RECIENTE DE PUBLICACIÓN2017
ÍNDICE H0

  • GRIPP2 reporting checklists

    Open AccessSophie Staniszewska, Jo Brett et al.ARTICLEResearch Involvement and Engagement2017

    While the patient and public involvement (PPI) evidence base has expanded over the past decade, the quality of reporting within papers is often inconsistent, limiting our understanding of how it works, in what context, for whom, and why. To develop international consensus on the key items to report to enhance the quality, transparency, and consistency of the PPI evidence base. To collaboratively involve patients as research partners at all stages…

  • GRIPP2 reporting checklists

    Open AccessSophie Staniszewska, Jo Brett et al.ARTICLEBMJ2017

    Background While the patient and public involvement (PPI) evidence base has expanded over the past decade, the quality of reporting within papers is often inconsistent, limiting our understanding of how it works, in what context, for whom, and why. Objective To develop international consensus on the key items to report to enhance the quality, transparency, and consistency of the PPI evidence base. To collaboratively involve patients as research p…

  • Long-Term Worries after Colposcopy

    Open AccessLinda Sharp, Seonaidh C Cotton et al.ARTICLEWomen s Health Issues2015

  • International standards for newborn weight, length, and head circumference by gestational age and sex

    Open AccessJose Villar, Joris Hemelaar et al.ARTICLEThe Lancet2014

  • The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

    Open AccessJulian P T Higgins, D G Altman et al.ARTICLEBMJ2011

    Flaws in the design, conduct, analysis, and reporting of randomised trials can cause the effect of an intervention to be underestimated or overestimated. The Cochrane Collaboration’s tool for assessing risk of bias aims to make the process clearer and more accurate

  • Consort 2010 Explanation and Elaboration

    Open AccessDavid Moher, Sally Hopewell et al.ARTICLEBMJ2010

    Overwhelming evidence shows the quality of reporting of randomised controlled trials (RCTs) is not optimal. Without transparent reporting, readers cannot judge the reliability and validity of trial findings nor extract information for systematic reviews. Recent methodological analyses indicate that inadequate reporting and design are associated with biased estimates of treatment effects. Such systematic error is seriously damaging to RCTs, which …

  • Improving the reporting of pragmatic trials

    Open AccessMerrick Zwarenstein, Shaun Treweek et al.ARTICLEBMJ2008

    BACKGROUND: The CONSORT statement is intended to improve reporting of randomised controlled trials and focuses on minimising the risk of bias (internal validity). The applicability of a trial's results (generalisability or external validity) is also important, particularly for pragmatic trials. A pragmatic trial (a term first used in 1967 by Schwartz and Lellouch) can be broadly defined as a randomised controlled trial whose purpose is to inform …

  • Multiple significance tests

    Open AccessJ Martin Bland, Martin Bland et al.ARTICLEBMJ1995

    Recent studies have shown that p53 contributes to poor survival during immune checkpoint blockade (ICB) therapy. Lung cancer patients with p53 mutations have significantly improved response rates to PD-1 ICB therapy. While previous studies have shown that tumor-derived IL-33 is required for the anti-tumor immune response and efficacy of ICB therapies, the relationship between p53 and IL-33 during ICB therapy is unknown. In this study, we characte…